种族对转移性前列腺癌生存的影响:一项系统性文献综述
该系统性文献综述按PRISMA指南检索2012年1月至2022年7月发表的真实世界研究,评估种族对转移性前列腺癌患者总生存和前列腺癌特异性死亡率的影响。共纳入54项独特研究(51项美国、3项美国以外),多数研究显示黑人、西班牙裔及美洲印第安人/阿拉斯加原住民患者与白人患者生存相似,而黑人在某些治疗下及亚洲患者生存更优。
要点
- 多数研究显示黑人vs白人转移性前列腺癌患者的总生存(21/27)和前列腺癌特异性死亡率(8/9)无差异。
- 多数研究显示黑人在某些转移性前列腺癌治疗下总生存更优(7/10)。
- 多数研究显示亚洲患者较白人总生存(3/4)和前列腺癌特异性死亡率(6/6)更优。
核心结论
- 多数研究显示黑人、西班牙裔及美洲印第安人/阿拉斯加原住民转移性前列腺癌患者与白人患者生存相似,而黑人在某些治疗下及亚洲患者生存更优。
- 未来研究需了解包括健康社会决定因素在内的种族相关方面如何驱动这些发现。
研究设计与样本
- 系统性文献综述,按PRISMA指南实施和报告。
- 检索MEDLINE、Embase和Cochrane Library(Ovid界面),纳入2012年1月至2022年7月发表的真实世界研究,并补充检索重要会议。
- 共识别3228条独特记录,纳入62条记录(47篇全文和15篇会议摘要),对应54项独特研究(51项美国、3项美国以外)。
- 对纳入研究进行偏倚风险评估。
主要发现
- 多数研究显示黑人vs白人患者总生存无差异(21/27)或前列腺癌特异性死亡率无差异(8/9)。
- 多数研究显示黑人在某些转移性前列腺癌治疗下总生存更优(7/10)。
- 多数研究显示白人vs西班牙裔患者总生存无差异(6/8)或前列腺癌特异性死亡率无差异(5/6)。
- 多数研究显示白人vs美洲印第安人/阿拉斯加原住民患者总生存无差异(2/3)或前列腺癌特异性死亡率无差异(5/5)。
- 多数研究显示亚洲患者vs白人患者总生存更优(3/4)和前列腺癌特异性死亡率更优(6/6)。
局限性
- 未来研究需了解包括健康社会决定因素在内的种族相关方面如何驱动这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PC) is the second most diagnosed cancer in men worldwide. While racial and ethnic differences exist in incidence and mortality, increasing data suggest outcomes by race among men with newly diagnosed PC are similar. However, outcomes among races beyond Black/White have been poorly studied. Moreover, whether outcomes differ by race among men who all have metastatic PC (mPC) is unclear. This systematic literature review (SLR) provides a comprehensive synthesis of current evidence relating race to survival in mPC. METHODS: An SLR was conducted and reported in accordance with PRISMA guidelines. MEDLINE®, Embase, and Cochrane Library using the Ovid® interface were searched for real-world studies published from January 2012 to July 2022 investigating the impact of race on overall survival (OS) and prostate cancer-specific mortality (PCSM) in patients with mPC. A supplemental search of key congresses was also conducted. Studies were appraised for risk of bias. RESULTS: Of 3228 unique records identified, 62 records (47 full-text and 15 conference abstracts), corresponding to 54 unique studies (51 United States and 3 ex-United States) reporting on race and survival were included. While most studies showed no difference between Black vs White patients for OS (n = 21/27) or PCSM (n = 8/9), most showed that Black patients demonstrated improved OS on certain mPC treatments (n = 7/10). Most studies found no survival difference between White patients and Hispanic (OS: n = 6/8; PCSM: n = 5/6) or American Indian/Alaskan Native (AI/AN) (OS: n = 2/3; PCSM: n = 5/5). Most studies found Asian patients had improved OS (n = 3/4) and PCSM (n = 6/6) vs White patients. CONCLUSIONS: Most studies found Black, Hispanic, and AI/AN patients with mPC had similar survival as White patients, while Black patients on certain therapies and Asian patients showed improved survival. Future studies are needed to understand what aspects of race including social determinants of health are driving these findings.
引用
- Freedland SJ, Samjoo IA, Rosta E, et al. The impact of race on survival in metastatic prostate cancer: a systematic literature review. Prostate Cancer Prostatic Dis. 2023. PMID: 37592001. doi:10.1038/s41391-023-00710-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。